Fig. 3
Biocompatibility and mechanism of drug release. (A) Viability of L929 cells was determined on day 3 using the WST-1 assay. (B) Predicted IC50, representing the concentration at which 50% cell (N2a) survival was observed, was determined to be 20 µM for CLB. (C) Cellular uptake of FITC-labeled SHAP in RAW264.7 macrophages. Scale bar = 50 μm. (D) TEM images of RAW-264.7 cells cultured with SHAP − CLB were obtained to investigate their interactions at the cellular level. (i) The interface between RAW-264.7 cells and SHAP − CLB particles prior to cellular uptake. Scale bar = 0.5 μm. (ii) RAW-264.7 cells can be observed engulfing and enclosing SHAP − CLB particles within endosomes. Scale bar = 2 μm. (iii) The indentation of the cell membrane during the process of endocytosis is depicted in Figure. Scale bar = 0.5 μm. (iv) The SHAP − CLB particles transported to the lysosomes. Scale bar = 1 μm